In a Chinese phase 3 trial (LungTIME-C01) involving 210 patients with advanced non-small cell lung cancer, administering anti-PD-1 immunotherapy before 3:00 PM nearly doubled progression-free survival (11.3 vs. 5.7 months) and significantly improved overall survival (28.0 vs. 16.8 months) compared to later infusions. This early time-of-day treatment was linked to a more robust anti-tumor immune response, characterized by increased levels of activated CD8+ T cells and a more favorable ratio of activated to exhausted T cells, with no increase in treatment-related adverse events. The findings suggest that simply shifting immunochemotherapy to early time-of-day can profoundly enhance efficacy for patients. Source: https://www.nature.com
Restricting sugar intake during the first 1,000 days from conception was associated with a lower…
Incidental coronary artery calcium (CAC) identified on routine nongated chest CT scans predicts future coronary…
The burden of modifiable cardiovascular risk factors—not just the total number of risk factors—is strongly…
Higher blood levels of the gut microbiome-derived metabolite trimethylamine N-oxide (TMAO) were independently associated with…
Moderate consumption of naturally caffeinated beverages, particularly coffee, is generally associated with a lower risk…
To reduce the risk of cognitive decline and/or dementia specifically, the WHO just released updated…
This website uses cookies.